Get the Stockscreener App
26.06
0.04%
0.010
After Hours:
25.40
-0.66
-2.53%
Arcus Biosciences Inc stock is traded at $26.06, with a volume of 1.15M.
It is up +0.04% in the last 24 hours and up +13.50% over the past month.
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.
See More
Previous Close:
$26.05
Open:
$26.39
24h Volume:
1.15M
Relative Volume:
0.94
Market Cap:
$3.27B
Revenue:
$247.00M
Net Income/Loss:
$-353.00M
P/E Ratio:
-7.8963
EPS:
-3.3003
Net Cash Flow:
$-484.00M
1W Performance:
+5.08%
1M Performance:
+13.50%
6M Performance:
+31.95%
1Y Performance:
+191.50%
1-Day Range:
$25.25
$26.70
1-Week Range:
$23.91
$26.70
52-Week Range:
$7.06
$28.72
Arcus Biosciences Inc Stock (RCUS) Company Profile
Name
Arcus Biosciences Inc
Sector
Industry
Phone
(510) 694-6200
Address
3928 POINT EDEN WAY, HAYWARD, CA
Compare RCUS vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RCUS
Arcus Biosciences Inc
|
26.06 | 3.27B | 247.00M | -353.00M | -484.00M | -3.3003 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Arcus Biosciences Inc Stock (RCUS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-12-26 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-13-26 | Upgrade | Goldman | Neutral → Buy |
| Jan-08-26 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-26-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-21-24 | Initiated | H.C. Wainwright | Neutral |
| Oct-08-24 | Initiated | Wells Fargo | Overweight |
| Nov-18-22 | Initiated | BofA Securities | Neutral |
| Oct-11-22 | Initiated | Morgan Stanley | Overweight |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Nov-24-20 | Initiated | Berenberg | Buy |
| Nov-23-20 | Initiated | Evercore ISI | Outperform |
| Apr-03-20 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Sep-27-19 | Initiated | Mizuho | Buy |
| May-24-19 | Resumed | Citigroup | Buy |
| Oct-09-18 | Initiated | Wedbush | Outperform |
| Apr-09-18 | Initiated | Citigroup | Buy |
| Apr-09-18 | Initiated | Goldman | Neutral |
| Apr-09-18 | Initiated | Leerink Partners | Outperform |
View All
Arcus Biosciences Inc Stock (RCUS) Latest News
Arcus (RCUS) Q1 2026 Earnings Call Transcript - AOL.com
Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance
Earnings call transcript: Arcus Biosciences Q1 2026 results miss expectations - Investing.com
Arcus Biosciences Q1 Loss Narrows, Revenue Falls - marketscreener.com
Earnings Flash (RCUS) Arcus Biosciences Posts Q1 EPS -$1.02, vs. FactSet Est of -$0.88 - marketscreener.com
Earnings Flash (RCUS) Arcus Biosciences, Inc. Reports Q1 Revenue $17.0M, vs. FactSet Est of $29.5M - marketscreener.com
Arcus Biosciences (RCUS) Q1 2026 loss widens amid Gilead shift and trial setback - Stock Titan
Arcus Biosciences (NYSE: RCUS) details Q1 loss, cash runway and trial shifts - Stock Titan
Arcus lines up 2026 kidney cancer trial milestones with $876M cash - Stock Titan
MSN Money - MSN
Arcus Biosciences in the spotlight: Earnings test casdatifan focus By Investing.com - Investing.com South Africa
Arcus Biosciences Inc (RCUS) Q1 2026: Everything You Need To Kno - GuruFocus
Understanding Momentum Shifts in (RCUS) - Stock Traders Daily
Is Trial Failures And Gilead Pullback Altering The Investment Case For Arcus Biosciences (RCUS)? - Sahm
Arcus Advances Quemliclustat With Completed Phase 1 Metabolism Study - TipRanks
What's going on with Arcus Biosciences stock on Wednesday? - MSN
Assessing Arcus Biosciences (RCUS) Valuation After STAR-121 Termination And Gilead Option Changes - Sahm
Arcus Biosciences, Inc. (RCUS) may report negative earnings: Know the trend ahead of next week's release - MSN
Arcus Biosciences (RCUS) to Release Quarterly Earnings on Tuesday - MarketBeat
Arcus Biosciences, Inc. (RCUS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - Yahoo Finance
Arcus halts Gilead-partnered late-stage trial for lung cancer drug - MSN
Arcus Biosciences: TIGIT In The Rearview Mirror, But Market Pricing A Bit Too Aggressively For Now - Seeking Alpha
Arcus Biosciences (RCUS) Is Up 5.2% After Lung Trial Futility Results And Gilead Option Shift - Yahoo Finance
New Arcus hire gets 4,200 options and 2,100 RSUs under plan - Stock Titan
Arcus Biosciences Announces New Employment Inducement Grants - marketscreener.com
Arcus Biosciences (RCUS) moves 7.8% higher: Will this strength last? - MSN
Gilead’s Arcus Pullback and Idvynso HIV Challenge Might Change The Case For Investing In GILD - Yahoo Finance
RCUS insider files Form 144; plans to sell 53,826 shares (NYSE: RCUS) - Stock Titan
Arcus Biosciences stock hits 52-week high at 26.5 USD By Investing.com - Investing.com India
Arcus Biosciences (NYSE:RCUS) Hits New 1-Year HighShould You Buy? - MarketBeat
Avoiding Lag: Real-Time Signals in (RCUS) Movement - Stock Traders Daily
What's Going On With Arcus Biosciences Stock On Wednesday? - Benzinga
Arcus Biosciences (RCUS) Sees 12.2% Surge in Stock Price - GuruFocus
Arcus Biosciences stock hits 52-week high at 26.5 USD - Investing.com
Arcus Biosciences (NYSE:RCUS) Trading Up 12.7%Here's Why - MarketBeat
Arcus Biosciences (RCUS) Moves 7.8% Higher: Will This Strength Last? - Yahoo Finance
[ARS] Arcus Biosciences, Inc. SEC Filing - Stock Titan
Arcus Biosciences : to Host Conference Call to Discuss First-Quarter 2026 Financia... - marketscreener.com
Cancer drug developer Arcus sets May 5 webcast on Q1 results - Stock Titan
Arcus Biosciences (NYSE: RCUS) details 2026 virtual shareholder meeting votes - Stock Titan
Merck's LITESPARK-012 Trial Results Could Benefit Arcus Bioscien - GuruFocus
Arcus Biosciences (NYSE:RCUS) Shares Gap DownWhat's Next? - MarketBeat
Arcus Biosciences Inc Stock (RCUS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):